Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Weitzman

Showing results (141-150 of 147) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 147 results.
The Journal of Experimental Medicine|December 12, 2019
Human tau pathology transmits glial tau aggregates in the absence of neuronal tauSneha Narasimhan, Lakshmi Changolkar, Dawn M Riddle, et al.
Journal of Clinical Pharmacology|September 14, 2013
Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) projectS M Belknap, C H Georgopoulos, J Lagman, et al.
Free Radical Biology & Medicine|June 16, 2009
Role of mitochondrial hOGG1 and aconitase in oxidant-induced lung epithelial cell apoptosisV Panduri, G Liu, S Surapureddi, et al.
Seminars in Oncology|December 22, 1999
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancerD P Petrylak, R Macarthur, J O'Connor, et al.
Cell Reports|November 27, 2024
Development of MAPT S305 mutation human iPSC lines exhibiting elevated 4R tau expression and functional alterations in neurons and astrocytesKathryn R Bowles, Chiara Pedicone, Derian A Pugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylateDavid A Dorr, Rachel Burdon, Dennis P West, et al.
Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.
Pageof 15

Showing results (141-150 of 147) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 147 results.
The Journal of Experimental Medicine|December 12, 2019
Human tau pathology transmits glial tau aggregates in the absence of neuronal tauSneha Narasimhan, Lakshmi Changolkar, Dawn M Riddle, et al.
Journal of Clinical Pharmacology|September 14, 2013
Reporting of serious adverse events during cancer clinical trials to the institutional review board: an evaluation by the research on adverse drug events and reports (RADAR) projectS M Belknap, C H Georgopoulos, J Lagman, et al.
Free Radical Biology & Medicine|June 16, 2009
Role of mitochondrial hOGG1 and aconitase in oxidant-induced lung epithelial cell apoptosisV Panduri, G Liu, S Surapureddi, et al.
Seminars in Oncology|December 22, 1999
Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancerD P Petrylak, R Macarthur, J O'Connor, et al.
Cell Reports|November 27, 2024
Development of MAPT S305 mutation human iPSC lines exhibiting elevated 4R tau expression and functional alterations in neurons and astrocytesKathryn R Bowles, Chiara Pedicone, Derian A Pugh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 22, 2009
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylateDavid A Dorr, Rachel Burdon, Dennis P West, et al.
Archives of Internal Medicine|May 30, 2007
Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturersCharles L Bennett, Jonathan R Nebeker, Paul R Yarnold, et al.
Pageof 15